Results 161 to 170 of about 168,078 (280)

When Public Health Becomes the Weapon: Current and Prospective Consequences of the Genocide in Gaza

World Medical &Health Policy, Volume 18, Issue 2, June 2026.
ABSTRACT Catastrophic humanitarian conditions during the 2023–2025 genocide in Gaza have caused a public health crisis of exceptional magnitude. This article summarizes key short‐ and long‐term health consequences for Gaza's civilian population and outlines priorities for recovery.
Therese Alexandra Evald, Nanna Gram Ahlmark, Clara Barfod Parellada, Andreea Micula, Caroline Klint Johannesen, Dana Bdier, Fayez Mahamid, Hilde Lausund, Jane Brandt Sørensen, Maha Aon, Majd Qannita, Maren Johanne Heilskov Rytter, Nanna Maaløe, Nina Jøranson, Sara Aakre Faradonbeh, Vibeke Brix Christensen, Waseem Alzaanin, Sigurd Lauridsen, Helle Timm, Frederik Schou‐Juul   +19 more
wiley   +1 more source

Correlation Analysis Between HLA Polymorphisms and Immune Response to Hepatitis B Vaccine in Children with Acute Lymphoblastic Leukemia. [PDF]

Vaccines (Basel)
Zhang R, Yang T, Gao Y, Zhang H, Fei Y, Yang L, Deng P.   +6 more
europepmc   +1 more source

Safe and Localized Lentiviral Gene Delivery via Injectable Mesoporous Scaffolds for Potent Antitumor Immunity

Advanced Materials, Volume 38, Issue 25, 4 May 2026.
This work introduces an injectable mesoporous silica rod scaffold that confines lentiviral vectors to the injection site, enabling localized dendritic cell recruitment and transduction. The platform sustains antigen expression, promotes robust T‐cell activation, and enhances antitumor immunity.
Thanh Loc Nguyen, Yeon‐ju Kim, Jihye Im, Dong Kwang Min, Hyunsu Shin, Thuy An Trinh, Ngoc Man Phan, Min‐jeong Son, Ji‐yeon Shim, Ye‐lim Lee, Yujeong Ha, Kwang‐il Lim, Jaeyun Kim   +12 more
wiley   +1 more source

Therapeutic hepatitis B vaccine employing DNA prime - MVA boost scheme requires additional priming with recombinant HBsAg to elicit an adequate antibody response. [PDF]

Front Immunol
Kerth HA, Kächele M, Müller N, Singh S, Tulessin M, Sacherl J, Ates Öz E, Su J, Bester R, Miko S, Steiger K, Mogler C, Busch DH, Wettengel JM, Protzer U, Kosinska AD.   +15 more
europepmc   +1 more source

Manufacturing and clinical applications of non‐CAR‐T immune effector cells

Transfusion, EarlyView.
Thane Kubik, Theodros Mamo, David H. McKenna   +2 more
wiley   +1 more source

Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies

Advanced Science, Volume 13, Issue 25, 4 May 2026.
The schematic diagram illustrates the roles of novel immune checkpoints, immunomodulatory factors, cell death and multimodal technologies in cancer immunotherapy. Abstract Cancer immunotherapy has redefined cancer treatment. However, the molecular and cellular basis of immune evasion and therapeutic resistance remains incompletely understood.
Fangquan Chen, Yang Yu, Xiutao Cai, Junhao Lin, Ruirui Liang, Rui Kang, Daolin Tang, Jiao Liu   +7 more
wiley   +1 more source

Interleukin-12 as a Predictor for Unresponsiveness to the Hepatitis B Vaccine: A Novel Cut-Off Point in Children. [PDF]

Children (Basel)
Ermaya YS, Sribudiani Y, Ghrahani R, Hock QS, Prasetyo D.   +4 more
europepmc   +1 more source

Introduction of the Hepatitis B Vaccine-Birth Dose: Methods of Improving Rates in a Milieu of Vaccine Hesitancy. [PDF]

Vaccines (Basel), 2023
Belle Jarvis S, Fenton-Lee T, Small S.
europepmc   +1 more source

Vaccination and transfusion safety at the time of expanding use of live attenuated vaccines

Vox Sanguinis, EarlyView.
Pierre Tiberghien, Pierre Gallian, Virginie de La Taille, Caroline Bacquet, Syria Laperche   +4 more
wiley   +1 more source

Intratumoral Proton Density Fat Fraction Predicts the Outcome of HAIC Combined With PD‐1 Inhibitors in Advanced Hepatocellular Carcinoma

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background and Aims This study aimed to explore the predictive value of intratumoral proton density fat fraction (PDFF) and the clinical efficacy of hepatic arterial infusion chemotherapy (HAIC) combined with anti‐programmed cell death protein 1 (anti‐PD‐1) therapy in advanced hepatocellular carcinoma (HCC).
Yujie Ye, Yunzheng Li, Yanjun Lu, Yanchao Xu, Laizhu Zhang, Yican Zhu, Huan Li, Binghua Li, Min Zhou, Decai Yu   +9 more
wiley   +1 more source